Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Myeloma • Internal Medicine • Amyloidosis • Hematology
What options are available for patients with relapsed/refractory AL amyloidosis after Dara-CyBorD, other than clinical trial?
Answer from: Medical Oncologist at Academic Institution
No great answers, unfortunately. Lenalidomide still tends to make me a bit nervous in AL amyloidosis, as does carfilzomib in patients with known cardiac involvement. But pom-based regimens are an option, or carfilzomib-based in the appropriate population.If the patient's BMBx shows t(11;14) by FISH,...
Sign in or Register to read more